Bitty Venture Capitalism: How Europe Puts It Together
Executive Summary
Both healthcare and financial systems in Europe are fragmented national entities. For financial backers of early life science ventures, this lanscape adds risk to new business that do not exist in sectors unified by operational standards. And for those running start-ups, their choice of experienced, life-science-savvy capital suppliers is restricted.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.